Press Releases

January, 2026

Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline Read More »

June, 2025

Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health Read More »

January, 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1 Read More »

January, 2023

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development Read More »

November, 2022

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging Read More »

November, 2022

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases Read More »

February, 2022

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1 Read More »